^
Association details:
| Biomarker: | DLK1 expression |
|---|---|
| Cancer: | Neuroblastoma |
| Drug: | ADCT-701 (DNA replication inhibitor, DLK1-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract LB-B04: A multi-omic surfaceome study identifies DLK1 as an epigenetically regulated protein and immunotherapeutic target in neuroblastoma
Excerpt:
To date, ADCT-701 treatment resulted in maintained complete response (N=2), complete response (N=3) and stable disease (N=1) in models with high DLK1 expression...DLK1 is an epigenetically regulated immunotherapeutic target in neuroblastoma. ADCT-701 shows potent activity in preclinical models of NB and should be prioritized for clinical development.
DOI:
https://doi.org/10.1158/1535-7163.TARG-19-LB-B04
Source:
Title:
Abstract 744: ADCT-701, a novel pyrrolobenzodiazepine (PBD) dimer-based antibody-drug conjugate (ADC) targeting DLK1-expressing tumors
Excerpt:
In vitro, ADCT-701 demonstrated potent cytotoxicity in a panel of human cancer cell lines of different origin and levels of DLK-1...In vivo, ADCT-701 showed potent anti-tumor activity in the DLK1-expressing neuroblastoma-derived SK-N-FI xenograft in which a single dose of ADCT-701 at 0.5 or 1 mg/kg showed dose-dependent anti-tumor activity...In conclusion, ADCT-701 demonstrated potent and specific in vitro and in vivo anti-tumor activity in DLK-1-expressing cancer-derived models and it was stable and well tolerated in the rat, warranting further development of this ADC into the clinic.
DOI:
https://doi.org/10.1158/1538-7445.AM2018-744
